Results 181 to 190 of about 32,890 (266)

Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions. [PDF]

J Pers Med
Pool IA, Otten AT, Kosterink JGW, Dijkstra G, Mian P, Bourgonje AR.   +5 more
europepmc   +1 more source

Reporting quality of randomized clinical trials for anti-TNF agents for Chron's disease published from 2005 to date using the CONSORT statemen [PDF]

, 2015
Γκουγκουλής, Δημήτριος Α
core   +1 more source

Off-Label Ustekinumab and Vedolizumab in Pediatric Anti-TNFα Refractory IBD: Therapeutic Drug Monitoring Insights from a Case Series. [PDF]

Pharmaceuticals (Basel)
Cheli S, Mosini G, Battini V, Carnovale C, Radice S, Lebiu M, Cattoni A, Zuin G, Clementi E.   +8 more
europepmc   +1 more source

T cell and cytokine signatures as early predictors of response to IL-12/IL-23 inhibition in Crohn's disease. [PDF]

Front Immunol
Martín Arranz E, García-Ramirez L, Van Den Rym A, Suarez C, García-Solís B, Díaz-Iglesias N, López-Lera A, Corvillo F, Rueda García JL, Blanco-San Miguel P, Sánchez Azofra M, Poza Cordón J, Itan Y, López-Collazo E, Pérez de Diego R, Martín-Arranz MD.   +15 more
europepmc   +1 more source

<i>Chlamydia psittaci</i> pneumonia in a patient using ustekinumab therapy for Crohn's disease. [PDF]

ASM Case Rep
Dirks JAMC, Mulder L, Burgers K, Damoiseaux JGMC, Heddema ER.   +4 more
europepmc   +1 more source

Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open-Label, Parallel-Group Study. [PDF]

Clin Pharmacol Drug Dev
Chow V, Winkle PJ, Mytych DT, Cao J, Barragan C, Colbert A, Gupta S, Radziszewski W, Franklin J.   +8 more
europepmc   +1 more source

Characterizing superficial epidermolytic ichthyosis in a patient with KRT2 mutation responsive to ustekinumab. [PDF]

JAAD Case Rep
Zaino M, Jones J, Hu R, Choate K, Callen JP, Schadt CR.   +5 more
europepmc   +1 more source

Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn's disease in China. [PDF]

World J Gastroenterol
Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S.   +5 more
europepmc   +1 more source

Comparative risk of <i>Clostridioides difficile</i> infection in patients with Crohn's disease receiving ustekinumab versus anti-TNF therapy: a retrospective cohort study. [PDF]

Ther Adv Gastroenterol
Huang J, Zhang M, Deng J, Yao J, Peng X, Zhang Q, Zhi M, Liu T.   +7 more
europepmc   +1 more source

Ustekinumab as a novel treatment of chronic nonbacterial osteomyelitis: a case report. [PDF]

AME Case Rep
Betcher A, Siegel R, Aggarwal K, Chen Y.
europepmc   +1 more source